**Supplemental Table 2**

|  |  |  |  |
| --- | --- | --- | --- |
| Network Name | Feature Name | p-value | OR |
| All Patients | CV\_cough\_threshold\_flag |  <1e-10 | 21 |
| All Patients | CV\_lympho\_threshold\_flag |  <1e-10 | 55 |
| Inpatients pre-COVID-19+ PCR Test | CV\_lympho\_threshold\_flag |  <1e-10 | 10 |
| Inpatients age 60+ | CV\_lympho\_threshold\_flag |  <1e-10 | 7.2 |
| All Patients | CV\_temp\_threshold\_flag |  <1e-10 | 17 |
| Inpatients Hispanic pre-COVID-19+ PCR Test | CV\_temp\_threshold\_flag | 2.00E-08 | 3.6 |
| Inpatients pre-COVID-19+ PCR Test | CV\_temp\_threshold\_flag |  <1e-10 | 2.7 |
| Inpatients age 60 to 69 | DG\_>28d\_postCOVID | J12.89 | Other viral pneumonia | 6.00E-06 | 27 |
| Inpatients post-COVID-19+ PCR Test | DG\_>28d\_postCOVID | J12.89 | Other viral pneumonia |  <1e-10 | 8.7 |
| Inpatients age < 60 | DG\_>28d\_postCOVID | J80 | Acute respiratory distress syndrome | 7.00E-07 | 9.9 |
| Inpatients age 60 to 69 | DG\_>28d\_postCOVID | J80 | Acute respiratory distress syndrome | 2.00E-04 | 7 |
| Inpatients age < 60 | DG\_>28d\_postCOVID | R50.9 | Fever unspecified | 0.04 | 2.8 |
| Inpatients age 60+ | DG\_>28d\_postCOVID | R65.21 | Severe sepsis with septic shock |  <1e-10 | 14 |
| Inpatients | DG\_>28d\_postCOVID | Z51.5 | Encounter for palliative care |  <1e-10 | 10 |
| Inpatients post-COVID-19+ PCR Test | DG\_>28d\_postCOVID | Z51.5 | Encounter for palliative care |  <1e-10 | 10 |
| Inpatients post-COVID-19+ PCR Test | DG\_>28d\_postCOVID | Z66 | Do not resuscitate |  <1e-10 | 7.6 |
| Inpatients post-COVID-19+ PCR Test | DG\_7dto14d\_postCOVID | Z51.5 | Encounter for palliative care | 7.00E-06 | 3.2 |
| All Patients | EP\_admittedToICU |  <1e-10 | 33 |
| Inpatients age < 60 pre-COVID-19+ PCR Test | EP\_admittedToICU |  <1e-10 | 12 |
| Inpatients age 60 to 69 | EP\_admittedToICU |  <1e-10 | 8.1 |
| Inpatients Hispanic | EP\_admittedToICU |  <1e-10 | 7.4 |
| Inpatients Hispanic pre-COVID-19+ PCR Test | EP\_admittedToICU |  <1e-10 | 7.4 |
| Inpatients White Non-Hispanic | EP\_admittedToICU |  <1e-10 | 7.4 |
| Inpatients White Non-Hispanic pre-COVID-19+ PCR Test | EP\_admittedToICU |  <1e-10 | 7.4 |
| Inpatients pre-COVID-19+ PCR Test | EP\_admittedToICU |  <1e-10 | 6.5 |
| Inpatients age 60+ | EP\_admittedToICU |  <1e-10 | 5.3 |
| Inpatients age 60+ pre-COVID-19+ PCR Test | EP\_admittedToICU |  <1e-10 | 5.3 |
| Inpatients age 70+ | EP\_admittedToICU |  <1e-10 | 4.5 |
| All Patients | EP\_placedOnVentilator |  <1e-10 | 170 |
| Inpatients age < 60 | EP\_placedOnVentilator |  <1e-10 | 170 |
| Inpatients age < 60 pre-COVID-19+ PCR Test | EP\_placedOnVentilator |  <1e-10 | 170 |
| Inpatients age 40 to 49 | EP\_placedOnVentilator |  <1e-10 | 85 |
| Inpatients age 60 to 69 | EP\_placedOnVentilator |  <1e-10 | 73 |
| Inpatients Hispanic | EP\_placedOnVentilator |  <1e-10 | 38 |
| Inpatients Hispanic pre-COVID-19+ PCR Test | EP\_placedOnVentilator |  <1e-10 | 38 |
| Inpatients African American Non-Hispanic pre-COVID-19+ PCR Test | EP\_placedOnVentilator |  <1e-10 | 36 |
| Inpatients | EP\_placedOnVentilator |  <1e-10 | 33 |
| Inpatients post-COVID-19+ PCR Test | EP\_placedOnVentilator |  <1e-10 | 33 |
| Inpatients pre-COVID-19+ PCR Test | EP\_placedOnVentilator |  <1e-10 | 33 |
| Inpatients White Non-Hispanic | EP\_placedOnVentilator |  <1e-10 | 24 |
| Inpatients White Non-Hispanic pre-COVID-19+ PCR Test | EP\_placedOnVentilator |  <1e-10 | 24 |
| Inpatients age 60+ | EP\_placedOnVentilator |  <1e-10 | 23 |
| Inpatients age 60+ pre-COVID-19+ PCR Test | EP\_placedOnVentilator |  <1e-10 | 23 |
| Inpatients age 70+ | EP\_placedOnVentilator |  <1e-10 | 19 |
| Inpatients age 40 to 49 | IM\_>28d\_postCOVID | albumin human | 0.009 | 18 |
| Inpatients | IM\_>28d\_postCOVID | albumin human |  <1e-10 | 9.9 |
| Inpatients post-COVID-19+ PCR Test | IM\_>28d\_postCOVID | albumin human |  <1e-10 | 9.9 |
| Inpatients post-COVID-19+ PCR Test | IM\_>28d\_postCOVID | amiodarone - NO MIDLINE IF IV |  <1e-10 | 19 |
| Inpatients White Non-Hispanic | IM\_>28d\_postCOVID | cisatracurium | 2.00E-10 | 150 |
| Inpatients | IM\_>28d\_postCOVID | cisatracurium |  <1e-10 | 52 |
| Inpatients Hispanic | IM\_>28d\_postCOVID | cisatracurium |  <1e-10 | 34 |
| Inpatients age < 60 | IM\_>28d\_postCOVID | Dextrose 10% in Water | 5.00E-05 | 7 |
| Inpatients age 60 to 69 | IM\_>28d\_postCOVID | Dextrose 5% in Water | 2.00E-04 | 7.3 |
| Inpatients post-COVID-19+ PCR Test | IM\_>28d\_postCOVID | Dextrose 5% in Water |  <1e-10 | 6 |
| Inpatients age 60 to 69 | IM\_>28d\_postCOVID | fentaNYL | 4.00E-08 | 23 |
| Inpatients age 70+ | IM\_>28d\_postCOVID | fentaNYL |  <1e-10 | 20 |
| Inpatients | IM\_>28d\_postCOVID | ketamine |  <1e-10 | 13 |
| Inpatients | IM\_>28d\_postCOVID | midazolam |  <1e-10 | 11 |
| Inpatients age 60 to 69 | IM\_>28d\_postCOVID | midazolam | 2.00E-05 | 9.7 |
| Inpatients Hispanic | IM\_>28d\_postCOVID | norepinephrine - NO MIDLINE IF IV |  <1e-10 | 30 |
| Inpatients age 60 to 69 | IM\_>28d\_postCOVID | norepinephrine - NO MIDLINE IF IV | 5.00E-09 | 26 |
| Inpatients age 60+ | IM\_>28d\_postCOVID | norepinephrine - NO MIDLINE IF IV |  <1e-10 | 25 |
| Inpatients age < 60 | IM\_>28d\_postCOVID | phenylephrine - NO MIDLINE IF IV | 0.002 | 7.1 |
| Inpatients White Non-Hispanic | IM\_>28d\_postCOVID | propofol - NO MIDLINE IF IV | 6.00E-10 | 68 |
| Inpatients post-COVID-19+ PCR Test | IM\_>28d\_postCOVID | sodium bicarbonate - NO MIDLINE IF IV |  <1e-10 | 19 |
| Inpatients age < 60 | IM\_>28d\_postCOVID | Sodium Chloride 0.9% | 0.003 | 5.4 |
| Inpatients post-COVID-19+ PCR Test | IM\_>28d\_postCOVID | sodium phosphate | 1.00E-07 | 6.4 |
| Inpatients Hispanic | IM\_>28d\_postCOVID | vasopressin - NO MIDLINE IF IV |  <1e-10 | 28 |
| Inpatients age 60 to 69 | IM\_14dto21d\_postCOVID | albumin human | 1.00E-06 | 8.4 |
| Inpatients age < 60 | IM\_14dto21d\_postCOVID | cisatracurium |  <1e-10 | 13 |
| Inpatients | IM\_14dto21d\_postCOVID | EPINEPHrine - NO MIDLINE IF IV |  <1e-10 | 23 |
| All Patients | IM\_14dto21d\_postCOVID | fentaNYL |  <1e-10 | 40 |
| Inpatients age 60 to 69 | IM\_14dto21d\_postCOVID | fentaNYL |  <1e-10 | 28 |
| Inpatients White Non-Hispanic | IM\_14dto21d\_postCOVID | fentaNYL |  <1e-10 | 25 |
| Inpatients Hispanic | IM\_14dto21d\_postCOVID | fentaNYL |  <1e-10 | 12 |
| Inpatients age 70+ | IM\_14dto21d\_postCOVID | ketamine | 6.00E-07 | 8.8 |
| Inpatients age 60 to 69 | IM\_14dto21d\_postCOVID | norepinephrine - NO MIDLINE IF IV | 1.00E-10 | 13 |
| Inpatients Hispanic | IM\_14dto21d\_postCOVID | norepinephrine - NO MIDLINE IF IV |  <1e-10 | 12 |
| Inpatients age < 60 | IM\_14dto21d\_postCOVID | NxStage dialysate | 0.002 | 8.7 |
| Inpatients Hispanic | IM\_14dto21d\_postCOVID | sodium bicarbonate - NO MIDLINE IF IV |  <1e-10 | 45 |
| Inpatients | IM\_21d-28d\_postCOVID | cisatracurium |  <1e-10 | 16 |
| Inpatients Hispanic | IM\_21d-28d\_postCOVID | fentaNYL |  <1e-10 | 18 |
| Inpatients age 70+ | IM\_21d-28d\_postCOVID | fentaNYL |  <1e-10 | 15 |
| Inpatients Hispanic | IM\_21d-28d\_postCOVID | midazolam |  <1e-10 | 16 |
| Inpatients age 60 to 69 | IM\_21d-28d\_postCOVID | norepinephrine - NO MIDLINE IF IV |  <1e-10 | 29 |
| Inpatients | IM\_7dto14d\_postCOVID | Dextrose 10% in Water |  <1e-10 | 5.1 |
| Inpatients age 70+ | IM\_7dto14d\_postCOVID | Dextrose 10% in Water |  <1e-10 | 4.9 |
| Inpatients | IM\_7dto14d\_postCOVID | Dextrose 5% in Water |  <1e-10 | 9.1 |
| Inpatients | IM\_7dto14d\_postCOVID | Dextrose 50% in Water |  <1e-10 | 5.7 |
| All Patients | IM\_7dto14d\_postCOVID | fentaNYL |  <1e-10 | 31 |
| Inpatients age 40 to 49 | IM\_7dto14d\_postCOVID | fentaNYL | 6.00E-06 | 16 |
| Inpatients White Non-Hispanic | IM\_7dto14d\_postCOVID | fentaNYL |  <1e-10 | 16 |
| Inpatients age 70+ | IM\_7dto14d\_postCOVID | fentaNYL |  <1e-10 | 14 |
| Inpatients age 60+ | IM\_7dto14d\_postCOVID | fentaNYL |  <1e-10 | 13 |
| Inpatients age < 60 | IM\_7dto14d\_postCOVID | Lactated Ringers Intravenous | 0.009 | 3.4 |
| Inpatients age < 60 | IM\_7dto14d\_postCOVID | NxStage dialysate | 6.00E-08 | 25 |
| Inpatients age 70+ | IM\_7dto14d\_postCOVID | potassium chloride | 6.00E-06 | 2.9 |
| Inpatients age 40 to 49 | IM\_7dto14d\_postCOVID | Sodium Chloride 0.9% | 0.002 | 5.9 |
| Inpatients pre-COVID-19+ PCR Test | IM\_upto1m\_preCOVID | cisatracurium | 4.00E-09 | 6.1 |
| Inpatients pre-COVID-19+ PCR Test | IM\_upto1m\_preCOVID | dexmedetomidine | 6.00E-04 | 3.5 |
| Inpatients White Non-Hispanic pre-COVID-19+ PCR Test | IM\_upto1m\_preCOVID | etomidate | 0.01 | 3.6 |
| Inpatients pre-COVID-19+ PCR Test | IM\_upto1m\_preCOVID | fentaNYL |  <1e-10 | 5.8 |
| Inpatients age 60+ pre-COVID-19+ PCR Test | IM\_upto1m\_preCOVID | fentaNYL | 3.00E-09 | 4.1 |
| Inpatients pre-COVID-19+ PCR Test | IM\_upto1m\_preCOVID | midazolam |  <1e-10 | 4.8 |
| Inpatients White Non-Hispanic pre-COVID-19+ PCR Test | IM\_upto1m\_preCOVID | midazolam | 0.001 | 3.8 |
| Inpatients pre-COVID-19+ PCR Test | IM\_upto1m\_preCOVID | norepinephrine - NO MIDLINE IF IV |  <1e-10 | 8.2 |
| Inpatients White Non-Hispanic pre-COVID-19+ PCR Test | IM\_upto1m\_preCOVID | norepinephrine - NO MIDLINE IF IV | 7.00E-06 | 5.8 |
| Inpatients age 60+ pre-COVID-19+ PCR Test | IM\_upto1m\_preCOVID | norepinephrine - NO MIDLINE IF IV | 3.00E-09 | 5 |
| Inpatients pre-COVID-19+ PCR Test | IM\_upto1m\_preCOVID | propofol - NO MIDLINE IF IV |  <1e-10 | 6 |
| Inpatients White Non-Hispanic pre-COVID-19+ PCR Test | IM\_upto1m\_preCOVID | propofol - NO MIDLINE IF IV | 5.00E-04 | 4.2 |
| Inpatients age 60+ pre-COVID-19+ PCR Test | IM\_upto1m\_preCOVID | propofol - NO MIDLINE IF IV | 9.00E-07 | 3.8 |
| Inpatients pre-COVID-19+ PCR Test | IM\_upto1m\_preCOVID | succinylcholine | 2.00E-04 | 4.8 |
| Inpatients pre-COVID-19+ PCR Test | IM\_upto1m\_preCOVID | tocilizumab | 0.03 | 2.7 |
| Inpatients African American Non-Hispanic pre-COVID-19+ PCR Test | IM\_upto1m\_preCOVID | vancomycin | 0.02 | 2.4 |
| All Patients | IM\_upto7d\_postCOVID | acetaminophen |  <1e-10 | 11 |
| Inpatients White Non-Hispanic | IM\_upto7d\_postCOVID | albumin human | 4.00E-10 | 11 |
| Inpatients age 60+ | IM\_upto7d\_postCOVID | albumin human |  <1e-10 | 7.5 |
| Inpatients age 60+ | IM\_upto7d\_postCOVID | amiodarone - NO MIDLINE IF IV |  <1e-10 | 9.6 |
| Inpatients White Non-Hispanic | IM\_upto7d\_postCOVID | calcium gluconate | 4.00E-10 | 20 |
| All Patients | IM\_upto7d\_postCOVID | cisatracurium |  <1e-10 | 55 |
| Inpatients White Non-Hispanic | IM\_upto7d\_postCOVID | cisatracurium |  <1e-10 | 12 |
| Inpatients age 70+ | IM\_upto7d\_postCOVID | cisatracurium |  <1e-10 | 11 |
| Inpatients Hispanic | IM\_upto7d\_postCOVID | cisatracurium |  <1e-10 | 7.7 |
| Inpatients age 60+ | IM\_upto7d\_postCOVID | dexmedetomidine |  <1e-10 | 5.8 |
| All Patients | IM\_upto7d\_postCOVID | Dextrose 10% in Water |  <1e-10 | 36 |
| Inpatients | IM\_upto7d\_postCOVID | Dextrose 10% in Water |  <1e-10 | 6.7 |
| Inpatients post-COVID-19+ PCR Test | IM\_upto7d\_postCOVID | Dextrose 10% in Water |  <1e-10 | 6.7 |
| Inpatients White Non-Hispanic | IM\_upto7d\_postCOVID | Dextrose 10% in Water |  <1e-10 | 5.8 |
| Inpatients Hispanic | IM\_upto7d\_postCOVID | Dextrose 10% in Water |  <1e-10 | 5.5 |
| Inpatients age 60+ | IM\_upto7d\_postCOVID | Dextrose 10% in Water |  <1e-10 | 4.3 |
| Inpatients age 70+ | IM\_upto7d\_postCOVID | Dextrose 10% in Water |  <1e-10 | 3.5 |
| Inpatients | IM\_upto7d\_postCOVID | Dextrose 50% in Water |  <1e-10 | 5.4 |
| All Patients | IM\_upto7d\_postCOVID | fentaNYL |  <1e-10 | 60 |
| Inpatients age 60 to 69 | IM\_upto7d\_postCOVID | fentaNYL |  <1e-10 | 14 |
| Inpatients White Non-Hispanic | IM\_upto7d\_postCOVID | fentaNYL |  <1e-10 | 13 |
| Inpatients age 60+ | IM\_upto7d\_postCOVID | fentaNYL |  <1e-10 | 11 |
| Inpatients age 70+ | IM\_upto7d\_postCOVID | fentaNYL |  <1e-10 | 10 |
| Inpatients Hispanic | IM\_upto7d\_postCOVID | fentaNYL |  <1e-10 | 7.6 |
| All Patients | IM\_upto7d\_postCOVID | furosemide |  <1e-10 | 33 |
| Inpatients White Non-Hispanic | IM\_upto7d\_postCOVID | furosemide |  <1e-10 | 8 |
| Inpatients age 60+ | IM\_upto7d\_postCOVID | furosemide |  <1e-10 | 4.8 |
| Inpatients White Non-Hispanic | IM\_upto7d\_postCOVID | insulin regular |  <1e-10 | 10 |
| Inpatients | IM\_upto7d\_postCOVID | insulin regular |  <1e-10 | 6.2 |
| Inpatients | IM\_upto7d\_postCOVID | ketamine |  <1e-10 | 7 |
| Inpatients age 40 to 49 | IM\_upto7d\_postCOVID | magnesium sulfate | 0.02 | 5.2 |
| All Patients | IM\_upto7d\_postCOVID | midazolam |  <1e-10 | 56 |
| Inpatients White Non-Hispanic | IM\_upto7d\_postCOVID | midazolam |  <1e-10 | 13 |
| Inpatients age 70+ | IM\_upto7d\_postCOVID | midazolam |  <1e-10 | 9.1 |
| Inpatients age 60+ | IM\_upto7d\_postCOVID | midazolam |  <1e-10 | 8.9 |
| All Patients | IM\_upto7d\_postCOVID | norepinephrine - NO MIDLINE IF IV |  <1e-10 | 76 |
| Inpatients White Non-Hispanic | IM\_upto7d\_postCOVID | norepinephrine - NO MIDLINE IF IV |  <1e-10 | 20 |
| Inpatients age 60 to 69 | IM\_upto7d\_postCOVID | norepinephrine - NO MIDLINE IF IV |  <1e-10 | 14 |
| Inpatients age 60+ | IM\_upto7d\_postCOVID | norepinephrine - NO MIDLINE IF IV |  <1e-10 | 11 |
| Inpatients age 70+ | IM\_upto7d\_postCOVID | norepinephrine - NO MIDLINE IF IV |  <1e-10 | 10 |
| Inpatients age 60 to 69 | IM\_upto7d\_postCOVID | ocular lubricant | 1.00E-04 | 8.8 |
| All Patients | IM\_upto7d\_postCOVID | propofol - NO MIDLINE IF IV |  <1e-10 | 69 |
| Inpatients age 60 to 69 | IM\_upto7d\_postCOVID | propofol - NO MIDLINE IF IV |  <1e-10 | 16 |
| Inpatients White Non-Hispanic | IM\_upto7d\_postCOVID | propofol - NO MIDLINE IF IV |  <1e-10 | 14 |
| Inpatients age 60+ | IM\_upto7d\_postCOVID | propofol - NO MIDLINE IF IV |  <1e-10 | 11 |
| Inpatients age 70+ | IM\_upto7d\_postCOVID | propofol - NO MIDLINE IF IV |  <1e-10 | 11 |
| Inpatients Hispanic | IM\_upto7d\_postCOVID | propofol - NO MIDLINE IF IV |  <1e-10 | 9 |
| Inpatients age 70+ | IM\_upto7d\_postCOVID | rocuronium | 3.00E-09 | 6.5 |
| Inpatients age 60+ | IM\_upto7d\_postCOVID | rocuronium |  <1e-10 | 6.5 |
| All Patients | IM\_upto7d\_postCOVID | Sodium Chloride 0.9% |  <1e-10 | 38 |
| Inpatients | IM\_upto7d\_postCOVID | tocilizumab |  <1e-10 | 3.9 |
| All Patients | IM\_upto7d\_postCOVID | vancomycin |  <1e-10 | 22 |
| Inpatients age 60 to 69 | IM\_upto7d\_postCOVID | vasopressin - NO MIDLINE IF IV | 2.00E-10 | 31 |
| Inpatients African American Non-Hispanic | LB\_>28d\_postCOVID | 1742-6 | ALT SerPl-cCnc | 0.002 | 9.9 |
| Inpatients post-COVID-19+ PCR Test | LB\_>28d\_postCOVID | 1742-6 | ALT SerPl-cCnc | 3.00E-06 | 4 |
| Inpatients African American Non-Hispanic | LB\_>28d\_postCOVID | 1920-8 | AST SerPl-cCnc | 7.00E-05 | 18 |
| Inpatients post-COVID-19+ PCR Test | LB\_>28d\_postCOVID | 1920-8 | AST SerPl-cCnc | 7.00E-10 | 6.1 |
| Inpatients age 70+ | LB\_>28d\_postCOVID | 61152-5 | Albumin SerPl BCP-mCnc | 2.00E-07 | 12 |
| Inpatients post-COVID-19+ PCR Test | LB\_>28d\_postCOVID | 61152-5 | Albumin SerPl BCP-mCnc |  <1e-10 | 7.6 |
| Inpatients age < 60 | LB\_>28d\_postCOVID | 6301-6 | INR PPP | 0.03 | 2.7 |
| Inpatients age 40 to 49 | LB\_>28d\_postCOVID | 742-7 | Monocytes # Bld Auto | 0.03 | 10 |
| Inpatients post-COVID-19+ PCR Test | LB\_14dto21d\_postCOVID | 61152-5 | Albumin SerPl BCP-mCnc |  <1e-10 | 5.3 |
| Inpatients post-COVID-19+ PCR Test | LB\_21d-28d\_postCOVID | 61152-5 | Albumin SerPl BCP-mCnc | 2.00E-09 | 6.6 |
| Inpatients age 50 to 59 | LB\_21d-28d\_postCOVID | 731-0 | Lymphocytes # Bld Auto | 0.04 | 4.1 |
| Inpatients age 50 to 59 | LB\_21d-28d\_postCOVID | 736-9 | Lymphocytes/leuk NFr Bld Auto | 0.004 | Inf |
| Inpatients age 40 to 49 | LB\_7dto14d\_postCOVID | 61152-5 | Albumin SerPl BCP-mCnc | 0.005 | 13 |
| Inpatients pre-COVID-19+ PCR Test | LB\_upto1m\_preCOVID | 711-2 | Eosinophil # Bld Auto | 0.004 | 3.3 |
| Inpatients pre-COVID-19+ PCR Test | LB\_upto1m\_preCOVID | 713-8 | Eosinophil/leuk NFr Bld Auto | 0.03 | 2.4 |
| Inpatients pre-COVID-19+ PCR Test | LB\_upto1m\_preCOVID | 742-7 | Monocytes # Bld Auto | 0.01 | 1.7 |
| Inpatients | LB\_upto7d\_postCOVID | 48067-3 | D dimer FEU PPP IA-mCnc |  <1e-10 | 4.1 |
| Inpatients post-COVID-19+ PCR Test | LB\_upto7d\_postCOVID | 48067-3 | D dimer FEU PPP IA-mCnc |  <1e-10 | 4.1 |
| Inpatients Hispanic | LB\_upto7d\_postCOVID | 61152-5 | Albumin SerPl BCP-mCnc |  <1e-10 | 5.1 |
| Inpatients Hispanic | PC\_upto7d\_postCOVID | 02HV33Z | Insertion of Infusion Device into Superior Vena Cava Percutaneous Approach |  <1e-10 | 12 |
| Inpatients age 70+ | PC\_upto7d\_postCOVID | 02HV33Z | Insertion of Infusion Device into Superior Vena Cava Percutaneous Approach |  <1e-10 | 11 |
| Inpatients White Non-Hispanic | PC\_upto7d\_postCOVID | 02HV33Z | Insertion of Infusion Device into Superior Vena Cava Percutaneous Approach | 4.00E-10 | 10 |
| Inpatients | PC\_upto7d\_postCOVID | 02HV33Z | Insertion of Infusion Device into Superior Vena Cava Percutaneous Approach |  <1e-10 | 10 |
| Inpatients age 60+ | PC\_upto7d\_postCOVID | 02HV33Z | Insertion of Infusion Device into Superior Vena Cava Percutaneous Approach |  <1e-10 | 8.6 |
| Inpatients age 60 to 69 | PC\_upto7d\_postCOVID | 02HV33Z | Insertion of Infusion Device into Superior Vena Cava Percutaneous Approach | 7.00E-09 | 8.2 |
| All Patients | PC\_upto7d\_postCOVID | 0BH17EZ | Insertion of Endotracheal Airway into Trachea Via Natural or Artificial Opening |  <1e-10 | 130 |
| Inpatients age 40 to 49 | PC\_upto7d\_postCOVID | 0BH17EZ | Insertion of Endotracheal Airway into Trachea Via Natural or Artificial Opening |  <1e-10 | 120 |
| Inpatients age 60 to 69 | PC\_upto7d\_postCOVID | 0BH17EZ | Insertion of Endotracheal Airway into Trachea Via Natural or Artificial Opening |  <1e-10 | 45 |
| Inpatients Hispanic | PC\_upto7d\_postCOVID | 0BH17EZ | Insertion of Endotracheal Airway into Trachea Via Natural or Artificial Opening |  <1e-10 | 37 |
| Inpatients age 60+ | PC\_upto7d\_postCOVID | 0BH17EZ | Insertion of Endotracheal Airway into Trachea Via Natural or Artificial Opening |  <1e-10 | 19 |
| Inpatients White Non-Hispanic | PC\_upto7d\_postCOVID | 0BH17EZ | Insertion of Endotracheal Airway into Trachea Via Natural or Artificial Opening |  <1e-10 | 16 |
| Inpatients age 70+ | PC\_upto7d\_postCOVID | 0BH17EZ | Insertion of Endotracheal Airway into Trachea Via Natural or Artificial Opening |  <1e-10 | 15 |
| All Patients | PC\_upto7d\_postCOVID | 5A1955Z | Respiratory Ventilation Greater than 96 Consecutive Hours |  <1e-10 | 94 |
| Inpatients age 40 to 49 | PC\_upto7d\_postCOVID | 5A1955Z | Respiratory Ventilation Greater than 96 Consecutive Hours | 7.00E-10 | 39 |
| Inpatients age 60 to 69 | PC\_upto7d\_postCOVID | 5A1955Z | Respiratory Ventilation Greater than 96 Consecutive Hours |  <1e-10 | 20 |
| Inpatients Hispanic | PC\_upto7d\_postCOVID | 5A1955Z | Respiratory Ventilation Greater than 96 Consecutive Hours |  <1e-10 | 20 |
| Inpatients White Non-Hispanic | PC\_upto7d\_postCOVID | 5A1955Z | Respiratory Ventilation Greater than 96 Consecutive Hours |  <1e-10 | 18 |
| Inpatients age 60+ | PC\_upto7d\_postCOVID | 5A1955Z | Respiratory Ventilation Greater than 96 Consecutive Hours |  <1e-10 | 13 |
| Inpatients age 70+ | PC\_upto7d\_postCOVID | 5A1955Z | Respiratory Ventilation Greater than 96 Consecutive Hours |  <1e-10 | 13 |
| Inpatients age 18 to 39 | PC\_upto7d\_postCOVID | MajorDiagnostic | 0.01 | 9.4 |
| Inpatients Hispanic | PC\_upto7d\_postCOVID | MinorDiagnostic |  <1e-10 | 6.3 |
| Inpatients | PC\_upto7d\_postCOVID | MinorDiagnostic |  <1e-10 | 3.7 |
| Inpatients post-COVID-19+ PCR Test | PC\_upto7d\_postCOVID | MinorDiagnostic |  <1e-10 | 3.7 |
| All Patients | PC\_upto7d\_postCOVID | MinorTherapeutic |  <1e-10 | 62 |
| Inpatients age 40 to 49 | PC\_upto7d\_postCOVID | MinorTherapeutic | 1.00E-08 | 29 |
| Inpatients Hispanic | PC\_upto7d\_postCOVID | MinorTherapeutic |  <1e-10 | 16 |
| Inpatients | PC\_upto7d\_postCOVID | MinorTherapeutic |  <1e-10 | 13 |
| Inpatients post-COVID-19+ PCR Test | PC\_upto7d\_postCOVID | MinorTherapeutic |  <1e-10 | 13 |
| Inpatients age 60+ | PC\_upto7d\_postCOVID | MinorTherapeutic |  <1e-10 | 9.3 |
| Inpatients White Non-Hispanic | PC\_upto7d\_postCOVID | MinorTherapeutic |  <1e-10 | 9.3 |
| Inpatients age 70+ | PC\_upto7d\_postCOVID | MinorTherapeutic |  <1e-10 | 6.9 |
| Inpatients age 50 to 59 | VS\_>28d\_postCOVID | 196805942 | Procalcitonin Lvl. | 0.002 | 3.9 |
| Inpatients age 50 to 59 | VS\_>28d\_postCOVID | 3336070 | O2 Saturation | 0.02 | 20 |
| Inpatients age < 60 | VS\_>28d\_postCOVID | 3336070 | O2 Saturation | 0.03 | 11 |
| Inpatients African American Non-Hispanic | VS\_>28d\_postCOVID | 3336070 | O2 Saturation | 0.009 | 10 |
| Inpatients age < 60 | VS\_over12m\_preCOVID | 196805942 | Procalcitonin Lvl. | 0.003 | 11 |